Bernstein reiterates Eli Lilly stock rating at Outperform with $1,300 target

Bernstein analysts reaffirmed their 'Outperform' rating and a bullish $1,300 price target for Eli Lilly and Company (LLY) on Tuesday, amid a broader market assessment of the pharmaceutical giant’s dominance in the weight-loss and diabetes medication sectors. The investment firm’s reiteration in New York reflects growing confidence in the company's long-term growth trajectory, driven primarily by the massive commercial success of its blockbuster drugs, Mounjaro and Zepbound. This optimistic outlook comes as Eli Lilly continues to distance itself from competitors through aggressive manufacturing expansions and clinical advancements. The $1,300 price target represents one of the most aggressive valuations on Wall Street, suggesting significant upside from the stock's current trading levels. Bernstein's analysis highlights that the demand for GLP-1 receptor agonists—used for both type 2 diabetes and obesity—surpasses the current supply, creating a favorable pricing environment and sustained revenue growth. Furthermore, the firm noted that Eli Lilly’s robust pipeline, which includes promising treatments for Alzheimer’s disease and other chronic conditions, provides a safety net beyond its core metabolic franchise. Market observers point to the company’s strategic capital allocation as a key differentiator. By reinvesting profits into high-tech manufacturing facilities in North Carolina and Germany, Eli Lilly is positioning itself to mitigate the supply chain bottlenecks that have plagued the industry over the last year. As the global obesity crisis intensifies, analysts expect the company to capture a lion's share of a market projected to reach $100 billion by the end of the decade, making it a cornerstone holding for institutional investors seeking health-tech exposure.